Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Risk Factors for Severe Infection and Unfavorable Outcomes in Hematologic Malignancy Patients with COVID-19 Inflection during the Omicron Era: A Chinese Single-Center Retrospective Study

Blood (2023) 142 (Supplement 1): 5384.

https://doi.org/10.1182/blood-2023-184470

Published: 2023

Journal Articles

CHEK1 and circCHEK1_246aa Promote Multiple Myeloma Malignancy By Evoking Chromosomal Instability and Bone Lesion

Ye Yang, PhD, Chunyan Gu, Wang Wang, Xiaozhu Tang

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-134206

Published: 2020

Journal Articles

RFWD2 Induces Cellular Proliferation and Proteasome Inhibitor Resistance By Mediating p27 Ubiqutinaiton in Multiple Myeloma

Ye Yang, PhD, Mengjie Guo, Chunyan Gu

Blood (2019) 134 (Supplement_1): 3068.

https://doi.org/10.1182/blood-2019-127888

Published: 2019

Journal Articles

Targeting NEK2 Induces Cellular Senescence in B-Cell Malignancies through p53-Independent Signaling Pathways

Yuqi Zhu, Ye Yang, PhD, Yogesh Jethava, MBBS,MDFRCPath,MRCP, Ivana Frech, DSc, PhD MBA, Guido J. Tricot, MD PhD, Fenghuang Zhan, MD PhD

Blood (2019) 134 (Supplement_1): 3102.

https://doi.org/10.1182/blood-2019-123815

Published: 2019

Journal Articles

Coexistence of a Huge Venous Thromboembolism and Bleeding Tendency in Cytokine Release Syndrome during CAR-T Therapy

Haiyan Liu, MD, Ye Yang, PhD, Hongming Huang, MD

Blood (2019) 134 (Supplement_1): 5590.

https://doi.org/10.1182/blood-2019-129389

Published: 2019

Journal Articles

The Efficacy of a Novel Oral Proteasome Inhibitor NNU546 in Multiple Myeloma

Ye Yang, PhD, Yongqiang Zhu, Chunyan Gu

Blood (2019) 134 (Supplement_1): 5586.

https://doi.org/10.1182/blood-2019-127927

Published: 2019

Journal Articles

FOXM1, CDK6 and Rb Dependent Drug Resistance and Senescence in Myeloma

Chunyan Gu, PhD, Ruini Chen, PhD, Xuefang Jing, PhD, Siegfried Janz, Ye Yang, PhD

Blood (2016) 128 (22): 4456.

https://doi.org/10.1182/blood.V128.22.4456.4456

Published: 2016

Journal Articles

MK2 Is a Therapeutic Target for High-Risk Multiple Myeloma

Chunyan Gu, PhD, Hongbao Yang, Hailin Peng, Zhiye Xu, Ruini Chen, PhD, Ye Yang, PhD

Blood (2016) 128 (22): 5612.

https://doi.org/10.1182/blood.V128.22.5612.5612

Published: 2016

Journal Articles

Targeting Neddylation to Overcome Drug Resistance in Multiple Myeloma

Gregory S Thomas, PhD, Junwei Huang, MD, Yi Zhou, PhD, Zhimin Gu, PhD, Ye Yang, PhD, Hongwei Xu, Guido J Tricot, MD PhD, Fenghuang Zhan, MD PhD

Blood (2015) 126 (23): 1804.

https://doi.org/10.1182/blood.V126.23.1804.1804

Published: 2015

Journal Articles

Decreased FPN1 in Myeloma Promotes Malignant Cell Growth and Osteoclast Differentiation

Zhimin Gu, PhD, He Wang, PhD, Jiliang Xia, MS, Ivana De Domenico, PhD, Ye Yang, PhD, Junwei Huang, MD, Hongwei Xu, DDS, Zhengdong Jin, PhD, Guido J. Tricot, MD, PhD, Fenghuang Zhan, MD PhD

Blood (2014) 124 (21): 2017.

https://doi.org/10.1182/blood.V124.21.2017.2017

Published: 2014

Journal Articles

NEK2 Suppresses Cellular Senescence through Regulation of the β-Catenin/CCND2/RB Axis in Multiple Myeloma

Ye Yang, PhD, Guido J. Tricot, MD, PhD, Xia Jiliang, Zhimin Gu, PhD, Hongwei Xu, DDS, Mu Hao, PhD, Fenghuang Zhan, MD PhD

Blood (2014) 124 (21): 2024.

https://doi.org/10.1182/blood.V124.21.2024.2024

Published: 2014

Journal Articles

Hypermethylation of TAp73 Suppresses ABL1-Involved DNA Damage Response in Multiple Myeloma

Mu Hao, PhD, Yu Qin, PhD, Meirong Zang, PhD, Yan Xu, MD PhD, Gang An, MD PhD, Changhong Li, MD, Ye Yang, PhD, Zhimin Gu, PhD, Fenghuang Zhan, MD PhD, Lugui Qiu, MD PhD

Blood (2014) 124 (21): 3374.

https://doi.org/10.1182/blood.V124.21.3374.3374

Published: 2014

Journal Articles

Elevated Expression Of CKS1B Inhibits Senescence Thorough Enhanced Degradation Of p21 In Multiple Myeloma

Zhimin Gu, PhD, Yi Zhou, PhD, He Wang, MD, Ye Yang, PhD, Hongwei Xu, DDS, Junwei Huang, MD, Jie He, MD, Yi Tao, MD&PhD, Guido J. Tricot, M.D., Ph.D., Fenghuang Zhan, MD&PhD

Blood (2013) 122 (21): 1882.

https://doi.org/10.1182/blood.V122.21.1882.1882

Published: 2013

Journal Articles

High Trip13 and Low P31 Comet Cause Drug Resistance and Poor Prognosis In Multiple Myeloma

Yi Tao, MD&PhD, Zhimin Gu, PhD, Ye Yang, PhD, Hongwei Xu, DDS, Xiaojing Hu, Guido J. Tricot, M.D., Ph.D., Fenghuang Zhan, MD&PhD, Jumei Shi, MD, PhD

Blood (2013) 122 (21): 3820.

https://doi.org/10.1182/blood.V122.21.3820.3820

Published: 2013

Journal Articles

RARα2 Expression Confers Myeloma Stem Cell Features

Guido J. Tricot, M.D., Ph.D., Ye Yang, PhD, Zhimin Gu, PhD, Hongwei Xu, DDS, Junwei Huang, MD, Jie He, MD, Yi Tao, MD&PhD, Fenghuang Zhan, MD&PhD

Blood (2013) 122 (21): 5404.

https://doi.org/10.1182/blood.V122.21.5404.5404

Published: 2013

Journal Articles

Targeting BTK As a Treatment For Multiple Myeloma Stem Cells

Ye Yang, PhD, Zhimin Gu, PhD, Hongwei Xu, DDS, Junwei Huang, MD, Jie He, MD, Yi Tao, MD&PhD, Guido J. Tricot, M.D., Ph.D., Fenghuang Zhan, MD&PhD

Blood (2013) 122 (21): 271.

https://doi.org/10.1182/blood.V122.21.271.271

Published: 2013

Journal Articles

RARα2 expression confers myeloma stem cell features

Ye Yang, Jumei Shi, Giulia Tolomelli, Hongwei Xu, Jiliang Xia, He Wang, Wen Zhou, Yi Zhou, Satyabrata Das, Zhimin Gu, Dana Levasseur, Fenghuang Zhan, Guido Tricot

Blood (2013) 122 (8): 1437–1447.

https://doi.org/10.1182/blood-2013-02-482919

Published: 2013

Includes: Supplemental data

Journal Articles

Skeletal-Targeted, Osteolytic-Responsive Drug Delivery System Improves Anti-Tumor Efficacy in Multiple Myeloma.

Xuli Wang, PhD, Ye Yang, PhD, Scott Miller, PhD, Fenghuang Zhan, MD, PhD

Blood (2012) 120 (21): 3155.

https://doi.org/10.1182/blood.V120.21.3155.3155

Published: 2012

Journal Articles

Phase I Exploratory Study of IV Formulation of Panobinostat in Combination with Bortezomib in Relapsed/Refractory Multiple Myeloma Patients: Effect On Serum PTH and Gene Expression Profiling (GEP) Studies

Maurizio Zangari, MD, Tamara Berno, MD, Giampaolo Talamo, MD, Xin Zhan, Wen Zhou, He Wang, Ye Yang, PhD, Jiliang Xia, Yi Zhou, Karen Pena, Leanne Lujan, Jessica Kohan, Mohamed E Salama, M.D., Fenghuang Zhan, MD, PhD

Blood (2012) 120 (21): 4073.

https://doi.org/10.1182/blood.V120.21.4073.4073

Published: 2012

Journal Articles

Inhibition of RARα2 or Its Downstream Signaling Pathways Decreases Drug Resistance in Myeloma

Guido J. Tricot, MD, PhD, Ye Yang, PhD, Fang Xiao, PhD, Maurizio Zangari, MD, Hongwei Xu, MD, MS, Fenghuang Zhan, MD, PhD

Blood (2011) 118 (21): 989.

https://doi.org/10.1182/blood.V118.21.989.989

Published: 2011

NARROW

Risk Factors for Severe Infection and Unfavorable Outcomes in Hematologic Malignancy Patients with COVID-19 Inflection during the Omicron Era: A Chinese Single-Center Retrospective Study

CHEK1 and circCHEK1_246aa Promote Multiple Myeloma Malignancy By Evoking Chromosomal Instability and Bone Lesion

RFWD2 Induces Cellular Proliferation and Proteasome Inhibitor Resistance By Mediating p27 Ubiqutinaiton in Multiple Myeloma

Targeting NEK2 Induces Cellular Senescence in B-Cell Malignancies through p53-Independent Signaling Pathways

Coexistence of a Huge Venous Thromboembolism and Bleeding Tendency in Cytokine Release Syndrome during CAR-T Therapy

The Efficacy of a Novel Oral Proteasome Inhibitor NNU546 in Multiple Myeloma

FOXM1, CDK6 and Rb Dependent Drug Resistance and Senescence in Myeloma

MK2 Is a Therapeutic Target for High-Risk Multiple Myeloma

Targeting Neddylation to Overcome Drug Resistance in Multiple Myeloma

Decreased FPN1 in Myeloma Promotes Malignant Cell Growth and Osteoclast Differentiation

NEK2 Suppresses Cellular Senescence through Regulation of the β-Catenin/CCND2/RB Axis in Multiple Myeloma

Hypermethylation of TAp73 Suppresses ABL1-Involved DNA Damage Response in Multiple Myeloma

Elevated Expression Of CKS1B Inhibits Senescence Thorough Enhanced Degradation Of p21 In Multiple Myeloma

High Trip13 and Low P31 Comet Cause Drug Resistance and Poor Prognosis In Multiple Myeloma

RARα2 Expression Confers Myeloma Stem Cell Features

Targeting BTK As a Treatment For Multiple Myeloma Stem Cells

RARα2 expression confers myeloma stem cell features

Skeletal-Targeted, Osteolytic-Responsive Drug Delivery System Improves Anti-Tumor Efficacy in Multiple Myeloma.

Phase I Exploratory Study of IV Formulation of Panobinostat in Combination with Bortezomib in Relapsed/Refractory Multiple Myeloma Patients: Effect On Serum PTH and Gene Expression Profiling (GEP) Studies

Inhibition of RARα2 or Its Downstream Signaling Pathways Decreases Drug Resistance in Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only